Clonality Results for Steady-State BM From CML Patients
| UPN . | Stage . | % Ph+ . | MNC . | CD34+HLA-DR+ . | CD34+HLA-DR− . | |||
|---|---|---|---|---|---|---|---|---|
| BCR/ABL . | CrR . | BCR/ABL . | CrR . | BCR/ABL . | CrR . | |||
| 1 | ECP | 100 | + | 0.25 | + | 0.41 | − | 0.63 |
| 2 | ECP | 90 | + | 0.19 | + | ND | + | 0.13 |
| 3 | ECP | 0 | + | ND | − | 1.47 | − | 1.34 |
| 5 | LCP | 100 | + | 5.22 | + | ND | + | 3.35 |
| 6 | LCP | 100 | + | 0.65 | + | 0.43 | ND | ND |
| 7 | LCP | 60 | + | 6.50 | + | 6.28 | ND | ND |
| 8 | LCP | 100 | + | 38.01 | + | 24.20 | + | 16.92 |
| 9 | AP | 100 | + | 12.24 | + | 29.74 | + | 34.24 |
| 10 | AP | 100 | + | 0.12 | + | 0.01 | ND | ND |
| 11 | AP | 43* | + | 1.30 | + | 1.71 | − | 1.41 |
| UPN . | Stage . | % Ph+ . | MNC . | CD34+HLA-DR+ . | CD34+HLA-DR− . | |||
|---|---|---|---|---|---|---|---|---|
| BCR/ABL . | CrR . | BCR/ABL . | CrR . | BCR/ABL . | CrR . | |||
| 1 | ECP | 100 | + | 0.25 | + | 0.41 | − | 0.63 |
| 2 | ECP | 90 | + | 0.19 | + | ND | + | 0.13 |
| 3 | ECP | 0 | + | ND | − | 1.47 | − | 1.34 |
| 5 | LCP | 100 | + | 5.22 | + | ND | + | 3.35 |
| 6 | LCP | 100 | + | 0.65 | + | 0.43 | ND | ND |
| 7 | LCP | 60 | + | 6.50 | + | 6.28 | ND | ND |
| 8 | LCP | 100 | + | 38.01 | + | 24.20 | + | 16.92 |
| 9 | AP | 100 | + | 12.24 | + | 29.74 | + | 34.24 |
| 10 | AP | 100 | + | 0.12 | + | 0.01 | ND | ND |
| 11 | AP | 43* | + | 1.30 | + | 1.71 | − | 1.41 |
Determination of the percent of Ph+ metaphases was performed on mononuclear cells by metaphase fluorescence in situ hybridization. BCR/ABL was scored as positive (+) if at least one of both RT-PCR reactions was positive, and scored as negative (−) if no BCR/ABL signal could be detected after Southern blotting despite positivity for β-actin. Calculation of mean CrR values for the HUMARA locus was performed as described in Materials and Methods.
Abbreviation: ND, not done.
57% of analyzed cells displayed the complex karyotypic abnormality: 45XX, t(4;22),−12, t(7;12).